335 related articles for article (PubMed ID: 29526098)
1. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors.
Yuan X; Wu H; Bu H; Zheng P; Zhou J; Zhang H
Bioorg Med Chem; 2019 Apr; 27(7):1211-1225. PubMed ID: 30824167
[TBL] [Abstract][Full Text] [Related]
3. Mnk inhibitors: a patent review.
Abdelaziz AM; Yu M; Wang S
Pharm Pat Anal; 2021 Jan; 10(1):25-35. PubMed ID: 33441033
[TBL] [Abstract][Full Text] [Related]
4. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors.
Abdelaziz AM; Basnet SKC; Islam S; Li M; Tadesse S; Albrecht H; Gerber C; Yu M; Wang S
Bioorg Med Chem Lett; 2019 Sep; 29(18):2650-2654. PubMed ID: 31362920
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold.
Jin X; Merrett J; Tong S; Flower B; Xie J; Yu R; Tian S; Gao L; Zhao J; Wang X; Jiang T; Proud CG
Eur J Med Chem; 2019 Jan; 162():735-751. PubMed ID: 30496989
[TBL] [Abstract][Full Text] [Related]
7. Optimization of 4,6-Disubstituted Pyrido[3,2-
Han Y; Zhang H; Wang S; Li B; Xing K; Shi Y; Cao H; Zhang J; Tong T; Zang J; Guan L; Gao X; Wang Y; Liu D; Huang M; Jing Y; Zhao L
J Med Chem; 2021 Sep; 64(18):13719-13735. PubMed ID: 34515481
[TBL] [Abstract][Full Text] [Related]
8. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
9. Progress in developing MNK inhibitors.
Jin X; Yu R; Wang X; Proud CG; Jiang T
Eur J Med Chem; 2021 Jul; 219():113420. PubMed ID: 33892273
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.
Zhang M; Jiang L; Tao J; Pan Z; He M; Su D; He G; Jiang Q
Bioorg Med Chem; 2019 Jun; 27(11):2268-2279. PubMed ID: 31014565
[TBL] [Abstract][Full Text] [Related]
11. Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.
Cherian J; Nacro K; Poh ZY; Guo S; Jeyaraj DA; Wong YX; Ho M; Yang HY; Joy JK; Kwek ZP; Liu B; Wee JL; Ong EH; Choong ML; Poulsen A; Lee MA; Pendharkar V; Ding LJ; Manoharan V; Chew YS; Sangthongpitag K; Lim S; Ong ST; Hill J; Keller TH
J Med Chem; 2016 Apr; 59(7):3063-78. PubMed ID: 27011159
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
15. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Grzmil M; Seebacher J; Hess D; Behe M; Schibli R; Moncayo G; Frank S; Hemmings BA
Cell Signal; 2016 Sep; 28(9):1412-1421. PubMed ID: 27289018
[TBL] [Abstract][Full Text] [Related]
17. BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity.
Santag S; Siegel F; Wengner AM; Lange C; Bömer U; Eis K; Pühler F; Lienau P; Bergemann L; Michels M; von Nussbaum F; Mumberg D; Petersen K
Cancer Lett; 2017 Apr; 390():21-29. PubMed ID: 28043914
[TBL] [Abstract][Full Text] [Related]
18. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
20. Discovery of indazole-pyridinone derivatives as a novel class of potent and selective MNK1/2 kinase inhibitors that protecting against endotoxin-induced septic shock.
Dreas A; Kucwaj-Brysz K; Pyziak K; Kulesza U; Wincza E; Fabritius CH; Michalik K; Gabor-Worwa E; Gołas A; Milik M; Masiejczyk M; Majewska E; Pyśniak K; Wójcik-Trechcińska U; Sandowska-Markiewicz Z; Brzózka K; Ostrowski J; Rzymski T; Mikula M
Eur J Med Chem; 2021 Mar; 213():113057. PubMed ID: 33303237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
